论文部分内容阅读
目的探讨头孢地尼联合奥硝唑治疗盆腔炎的临床疗效。方法选取南平市妇幼保健院2015年6月—2016年12月收治的盆腔炎患者70例,随机分为对照组和观察组,每组35例。对照组患者采用奥硝唑治疗,观察组患者在对照组基础上给予头孢地尼治疗,两组患者均以14 d为1个治疗周期。比较两组患者的临床疗效,治疗前后C反应蛋白(CRP)、白介素1(IL-1)水平及血细胞比容、血浆黏度,并观察患者不良反应发生情况。结果观察组患者临床疗效优于对照组(P<0.05)。治疗前,两组患者IL-1、CRP水平比较差异不显著(P>0.05);治疗后,观察组患者IL-1、CRP水平低于对照组,血细胞比容、血浆黏度低于对照组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论采用头孢地尼联合奥硝唑治疗盆腔炎临床疗效确切,可有效降低患者的炎性因子,改善机体血液流变学,且安全可靠。
Objective To investigate the clinical efficacy of cefdinir combined with ornidazole in the treatment of pelvic inflammatory disease. Methods Seventy patients with pelvic inflammatory disease admitted from Nanhui Maternal and Child Health Hospital from June 2015 to December 2016 were randomly divided into control group and observation group with 35 cases in each group. The patients in the control group were treated with ornidazole. The patients in the observation group were treated with cefdinir on the basis of the control group. Both groups were treated for 14 days as a treatment cycle. The clinical curative effect, C-reactive protein (CRP), interleukin-1 (IL-1) level, hematocrit and plasma viscosity were compared between the two groups before and after treatment. Results The clinical efficacy of the observation group was better than that of the control group (P <0.05). Before treatment, the levels of IL-1 and CRP in the two groups were not significantly different (P> 0.05). After treatment, the levels of IL-1 and CRP in the observation group were lower than those in the control group, the hematocrit and plasma viscosity were lower than those in the control group P <0.05). Two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusion The clinical effect of cefdinir combined with ornidazole in the treatment of pelvic inflammatory disease is exact, which can effectively reduce the inflammatory factors in patients and improve the blood rheology of the body, and is safe and reliable.